Comment on: Safety of thiopurines in Inflammatory Bowel Diseases: Neither so good, nor so bad

Simple item page
dc.contributor.authorFrancisca Carvajal
dc.contributor.authorRodrigo Quera
dc.contributor.authorGonzalo Pizarro
dc.contributor.authorChristian von Mühlenbrock
dc.contributor.authorPaulina Núñez
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T20:03:27Z
dc.date.available2026-03-22T20:03:27Z
dc.date.issued2026
dc.description.abstractIn recent decades, the treatment of inflammatory bowel disease (IBD) has changed markedly. Several biological therapies and small molecules have been approved, leading to improved outcomes and quality of life of these patients. However, access to these new therapies is heterogeneous across different countries. In this scenario, the use of thiopurines, through personalized treatment, remain a valid option.
dc.identifier.doi10.17235/reed.2026.11861/2026
dc.identifier.urihttps://doi.org/10.17235/reed.2026.11861/2026
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/79729
dc.language.isoen
dc.publisherArán Ediciones
dc.relation.ispartofRevista Española de Enfermedades Digestivas
dc.sourceUniversidad de Los Andes, Chile
dc.subjectMedicine
dc.subjectInflammatory bowel disease
dc.subjectInflammatory Bowel Diseases
dc.subjectInternal medicine
dc.subjectQuality of life (healthcare)
dc.subjectAzathioprine
dc.subjectDisease
dc.subjectIntensive care medicine
dc.subjectThiopurine methyltransferase
dc.subjectCrohn's disease
dc.titleComment on: Safety of thiopurines in Inflammatory Bowel Diseases: Neither so good, nor so bad
dc.typearticle

Files

Collections

Artículo Científico Publicado